伊库利珠单抗
重症肌无力
安慰剂
医学
耐火材料(行星科学)
临床终点
内科学
交叉研究
胃肠病学
补体系统
临床试验
免疫学
抗体
病理
物理
替代医学
天体生物学
作者
James F. Howard,Richard J. Barohn,Gary Cutter,Miriam Freimer,Vern C. Juel,Tahseen Mozaffar,Michelle Mellion,Michael Benatar,Maria Elena Farrugia,Jing Jing Wang,Suneil S. Malhotra,John T. Kissel
摘要
ABSTRACT Introduction : Complement activation at the neuromuscular junction is a primary cause of acetylcholine receptor loss and failure of neuromuscular transmission in myasthenia gravis (MG). Eculizumab, a humanized monoclonal antibody, blocks the formation of terminal complement complex by specifically preventing the enzymatic cleavage of complement 5 (C5). Methods : This study was a randomized, double‐blind, placebo‐controlled, crossover trial involving 14 patients with severe, refractory generalized MG (gMG). Results : Six of 7 patients treated with eculizumab for 16 weeks (86%) achieved the primary endpoint of a 3‐point reduction in the quantitative myasthenia gravis (QMG) score. Examining both treatment periods, the overall change in mean QMG total score was significantly different between eculizumab and placebo ( P = 0.0144). After assessing data obtained from all visits, the overall change in mean QMG total score from baseline was found to be significantly different between eculizumab and placebo ( P < 0.0001). Eculizumab was well tolerated. Conclusion : The data suggest that eculizumab may have a role in treating severe, refractory MG. Muscle Nerve, 2013
科研通智能强力驱动
Strongly Powered by AbleSci AI